Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ODC1 | P11926 | 1/20 | 0.37 |
| ▸ | ARG2 | P78540 | 5/20 | 0.33 |
| ▸ | ARG1 | P05089 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14764529 | 0.85 | MEN1 (0.52) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL1915862 | 0.84 | ARG2 (0.47) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL1916175 | 0.80 | ARG2 (0.53) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL14764832 | 0.79 | ARG1 (0.43) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL2049448 | 0.79 | CYP1A2 (0.33) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL1521206 | 0.78 | — | — | |
| SCHEMBL1916741 | 0.77 | ARG1 (0.45) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL30651 | 0.76 | ALDH1A1 (0.42) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL7431375 | 0.76 | — | — | |
| SCHEMBL12292622 | 0.74 | ARG1 (0.67) | ARG2ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | MEN1 2414/4885ALDH1A1 782/4885CYP1A2 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.